Sign In
Buy PRPO
$21.65
+0.460 (+2.17%)
At Close: Jul 31, 2026
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
10:00am, Tuesday, 08'th Oct 2024
The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients The unique assay enables laboratories to provide clinicians with more informed tre
Precipio Announces Employee Stock Option Plan Repricing
04:00pm, Friday, 06'th Sep 2024
NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock option
Zacks Initiates Coverage of Precipio With Outperform Recommendation
10:51am, Thursday, 05'th Sep 2024
Discover why Zacks rates Precipio as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore PRPO's approaching breakeven milestones, financial health, and market posit
Precipio, Inc. (PRPO) Q2 2024 Earnings Call Transcript
05:55pm, Monday, 19'th Aug 2024
Precipio, Inc. (NASDAQ:PRPO ) Q2 2024 Earnings Conference Call August 19, 2024 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Second Quarter 20
Precipio Announces Q2-2024 Shareholder Update Call
05:00pm, Thursday, 15'th Aug 2024
NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2024 corporate update call on August 19th at 5:00 P
Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
09:00am, Thursday, 25'th Jul 2024
Company's continued growth and improved cash position alleviates the need for capital raise in the foreseeable future Company's continued growth and improved cash position alleviates the need for capi
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
09:00am, Wednesday, 17'th Jul 2024
Pathology Revenues in June exceed breakeven target and continue growth trend Pathology Revenues in June exceed breakeven target and continue growth trend
Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
04:00pm, Thursday, 13'th Jun 2024
New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
04:00pm, Wednesday, 12'th Jun 2024
NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote
Precipio Secures a short-term $500K Credit Facility
05:00pm, Monday, 06'th May 2024
Loan will supplement any temporary cashflow deficit related to cash collections delay due to Change Healthcare cybersecurity attack Loan will supplement any temporary cashflow deficit related to cash
Precipio Announces Year end 2023 Shareholder Update Call
05:00pm, Monday, 25'th Mar 2024
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
10:00am, Tuesday, 13'th Feb 2024
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for the full year of 2023, its unaudited revenues have grown fro
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
10:00am, Tuesday, 06'th Feb 2024
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for i
Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
10:00am, Tuesday, 23'rd Jan 2024
Results clearly demonstrate the business's ability to reach breakeven in the near future Results clearly demonstrate the business's ability to reach breakeven in the near future
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
10:30am, Wednesday, 17'th Jan 2024
NEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an agreement with a Japanese distributor for the sa
